Full Press Release Details
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021.
ALT
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Key Takeaway: Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Price reaction · baseline $14.97 (2021-09-24 close) · 2 other ALT headline(s) in the window, move may be shared
day 0 close · peak
+1.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight